Enzyme replacement therapy and bony changes in Egyptian paediatric Gaucher disease patients
- PMID: 16601874
- DOI: 10.1007/s10545-006-0121-6
Enzyme replacement therapy and bony changes in Egyptian paediatric Gaucher disease patients
Abstract
Background: In Gaucher disease, the infiltration of the bone marrow by glucocerebroside-laden macrophages (Gaucher cells) triggers a diverse pattern of skeletal disease that results in crippling complications. Reliable ascertainment of the severity and pattern of skeletal disease is essential to determine disease status and the response to enzyme replacement therapy (ERT). Although there is ample documentation of reversal of haematological and visceral disease by ERT, there is a paucity of data on skeletal response to ERT in children.
Aim: To delineate the pattern of bone disease in children with Gaucher disease in Egypt and to evaluate its response to ERT.
Method: Twenty-two children with Gaucher disease were treated with ERT. Phenotyping by clinical, laboratory and radiological criteria was performed at baseline and following 11.2 +/- 4 months of ERT. Genotyping for glucocerebrosidase (GBA) mutations was performed by gene sequencing, and genotype-phenotype correlations were performed.Results. Two-thirds of the patients were from consanguineous pedigrees and 14/22 patients were homozygous or compound heterozygous for L444P and D409H mutations. Bone involvement was detected by plain radiology in 11 children (50%) and in 16 (73%) by magnetic resonance imaging (MRI). There was no correlation of severity of bone involvement and GBA genotype. ERT ameliorated bone disease: 10 of the 11 children with abnormal radiographic findings at baseline showed improvement in skeletal lesions; while 9/16 showed improvement of marrow disease by MRI. Radiographic sensitivity and specificity were 62% and 82% compared to MRI for detection of bone involvement in this patient population. At baseline, bone pain was present in 5 patients and ERT resulted in complete symptomatic remission in all of them. ERT was associated with significant improvement in growth parameters and amelioration of haematological and visceral involvement.
Conclusion: Symptomatic and radiological skeletal disease is common in children with Gaucher disease in Egypt. MRI is the most accurate technique for detecting early skeletal involvement. There was no correlation between severity of skeletal involvement and GBA genotype. ERT was effective in ameliorating radiological manifestations of skeletal disease and achieving complete remission of bone pain.
Similar articles
-
[Enzyme replacement therapy in Gaucher disease: monitoring visceral and bone changes with MRI].Orv Hetil. 2003 Apr 20;144(16):749-55. Orv Hetil. 2003. PMID: 12778625 Hungarian.
-
Use of plain radiography to optimize skeletal outcomes in children with type 1 Gaucher disease in Brazil.J Pediatr Orthop. 2007 Apr-May;27(3):347-50. doi: 10.1097/BPO.0b013e3180340d9f. J Pediatr Orthop. 2007. PMID: 17414023
-
Clinical-genetic characteristics and treatment outcomes of Turkish children with Gaucher disease type 1 and type 3: A sixteen year single-center experience.Eur J Med Genet. 2021 Nov;64(11):104339. doi: 10.1016/j.ejmg.2021.104339. Epub 2021 Sep 6. Eur J Med Genet. 2021. PMID: 34500086
-
Bone complications in children with Gaucher disease.Br J Radiol. 2002;75 Suppl 1:A37-44. doi: 10.1259/bjr.75.suppl_1.750037. Br J Radiol. 2002. PMID: 12036831 Review.
-
Gaucher disease among Chinese patients: review on genotype/phenotype correlation from 29 patients and identification of novel and rare alleles.Blood Cells Mol Dis. 2007 May-Jun;38(3):287-93. doi: 10.1016/j.bcmd.2006.11.003. Epub 2006 Dec 29. Blood Cells Mol Dis. 2007. PMID: 17196853 Review.
Cited by
-
Effect of glycosphingolipids on osteoclastogenesis and osteolytic bone diseases.Front Endocrinol (Lausanne). 2012 Aug 23;3:106. doi: 10.3389/fendo.2012.00106. eCollection 2012. Front Endocrinol (Lausanne). 2012. PMID: 22936926 Free PMC article.
-
Glycosphingolipid synthesis inhibition limits osteoclast activation and myeloma bone disease.J Clin Invest. 2015 Jun;125(6):2279-92. doi: 10.1172/JCI59987. Epub 2015 Apr 27. J Clin Invest. 2015. PMID: 25915583 Free PMC article.
-
Gaucher disease: a systematic review and meta-analysis of bone complications and their response to treatment.J Inherit Metab Dis. 2010 Jun;33(3):271-9. doi: 10.1007/s10545-010-9071-0. Epub 2010 Mar 25. J Inherit Metab Dis. 2010. PMID: 20336376
-
Long-term clinical outcomes in type 1 Gaucher disease following 10 years of imiglucerase treatment.J Inherit Metab Dis. 2013 May;36(3):543-53. doi: 10.1007/s10545-012-9528-4. Epub 2012 Sep 14. J Inherit Metab Dis. 2013. PMID: 22976765 Free PMC article.
-
Management of non-neuronopathic Gaucher disease with special reference to pregnancy, splenectomy, bisphosphonate therapy, use of biomarkers and bone disease monitoring.J Inherit Metab Dis. 2008 Jun;31(3):319-36. doi: 10.1007/s10545-008-0779-z. Epub 2008 May 23. J Inherit Metab Dis. 2008. PMID: 18509745 Review.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical